Author:
Jang Yoon Jung,Kim Eo Jin,Kim Hyung-Don,Kim Kyu-Pyo,Ryu Min-Hee,Park Sook Ryun,Choi Won-Mook,Lee Danbi,Choi Jonggi,Shim Ju Hyun,Kim Kang Mo,Lim Young-Suk,Lee Han Chu,Ryoo Baek-Yeol,Yoo Changhoon
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference21 articles.
1. Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J et al (2022) Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid 1(8):EVIDoa2100070
2. Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G et al (2018) cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology 68:113–126
3. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evalua- tion criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
4. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C et al (2017) Nivolumab in patients withadvanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389(10088):2492–2502
5. Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY et al (2020a) KEYNOTE-240 investigators pembrolizumab As second-Line therapy in patients with advanced hepatocellular carcinoma in Keynote-240: a randomized, double-blind. Phase III Trial. J Clin Oncol 38(3):193–202
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献